Active	Status	Sponsor type	Region	Phase	Filter
7 Active 7 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
zatolmilast (BPN14770) / Shionogi
NCT05367960: An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	Active, not recruiting	3	314	US	Zatolmilast/ BPN14770	Tetra Discovery Partners	Fragile X Syndrome	09/27	12/27
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome	Completed	3	171	US	BPN14770/ zatolmilast, Placebo	Tetra Discovery Partners	Fragile X Syndrome	07/25	07/25
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome	Completed	2/3	163	US	zatolmilast, BPN14770, Placebo	Tetra Discovery Partners	Fragile X Syndrome	09/25	09/25
NCT06717438: Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])	Active, not recruiting	2	30	US	BPN14770, Zatolmilast, Placebo	Shionogi	Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder	12/27	12/27
NCT07011992: A Study to Assess the Effects of BPN14770 on Rosuvastatin	Completed	1	12	US	Rosuvastatin, BPN14770, Zatolmilast	Shionogi	Healthy Participants	07/25	08/25
NCT07012005: Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls	Completed	1	14	US	BPN14770	Shionogi	Renal Impairment	12/25	12/25
NCT07018492: Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls	Completed	1	32	US	BPN14770	Shionogi	Hepatic Impairment	11/25	11/25